Business Description
Agenus Inc
NAICS : 325414
SIC : 2836
ISIN : US00847G8042
Total Employee Number:
81Description
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.85 | |||||
Equity-to-Asset | -1.19 | |||||
Debt-to-Equity | -0.19 | |||||
Debt-to-EBITDA | 0.32 | |||||
Interest Coverage | 0.14 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -14.1 | |||||
Beneish M-Score | 26.77 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -18 | |||||
3-Year EPS without NRI Growth Rate | 39.7 | |||||
3-Year FCF Growth Rate | 45.7 | |||||
3-Year Book Growth Rate | -24.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.86 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.48 | |||||
9-Day RSI | 63.48 | |||||
14-Day RSI | 56.59 | |||||
3-1 Month Momentum % | 2.35 | |||||
6-1 Month Momentum % | 10.83 | |||||
12-1 Month Momentum % | -28.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.38 | |||||
Quick Ratio | 0.38 | |||||
Cash Ratio | 0.14 | |||||
Days Sales Outstanding | 5.89 | |||||
Days Payable | 391.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.2 | |||||
Shareholder Yield % | -6.24 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 43.06 | |||||
Operating Margin % | 6.3 | |||||
Net Margin % | 52.16 | |||||
EBITDA Margin % | 102.55 | |||||
FCF Margin % | -70.66 | |||||
OCF Margin % | -70.66 | |||||
ROE % | Neg. Equity | |||||
ROA % | 31.28 | |||||
ROIC % | 2.76 | |||||
3-Year ROIIC % | -2006.11 | |||||
ROC (Joel Greenblatt) % | 169.53 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 2.17 | |||||
Forward PE Ratio | 2.65 | |||||
Price-to-Owner-Earnings | 2.53 | |||||
PS Ratio | 0.94 | |||||
EV-to-EBIT | 1.2 | |||||
EV-to-Forward-EBIT | 2.32 | |||||
EV-to-EBITDA | 1.13 | |||||
EV-to-Revenue | 1.16 | |||||
EV-to-Forward-Revenue | 1.09 | |||||
EV-to-FCF | -1.64 | |||||
Price-to-GF-Value | 0.83 | |||||
Price-to-Median-PS-Value | 0.2 | |||||
Earnings Yield (Greenblatt) % | 83.33 | |||||
FCF Yield % | -60.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AGEN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agenus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 123.866 | ||
| EPS (TTM) ($) | 1.59 | ||
| Beta | 1.8717 | ||
| 3-Year Sharpe Ratio | -0.33 | ||
| 3-Year Sortino Ratio | -0.49 | ||
| Volatility % | 58.98 | ||
| 14-Day RSI | 56.59 | ||
| 14-Day ATR ($) | 0.236214 | ||
| 20-Day SMA ($) | 3.131 | ||
| 12-1 Month Momentum % | -28.1 | ||
| 52-Week Range ($) | 2.71 - 7.34 | ||
| Shares Outstanding (Mil) | 41.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agenus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agenus Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 131 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-27 16:00 | In 57 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 | In 56 days | ||
| General meeting for 2026 | 2026-06-16 10:00 | 3.25 (-3.27%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:30 | 3.26 (-9.70%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 3.82 (+1.33%) | ||
| Guidance call for 2026 | 2026-03-31 16:30 | 3.24 (-4.42%) | ||
| Annual report for 2025 | 2026-03-16 | 3.10 (+2.65%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-16 | 3.10 (+2.65%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 3.10 (+2.65%) |
Show
Entries
Agenus Inc Frequently Asked Questions
What is Agenus Inc(AGEN)'s stock price today?
The current price of AGEN is $3.46. The 52 week high of AGEN is $7.34 and 52 week low is $2.71.
When is next earnings date of Agenus Inc(AGEN)?
The next earnings date of Agenus Inc(AGEN) is 2026-08-27 Est..
Does Agenus Inc(AGEN) pay dividends? If so, how much?
Agenus Inc(AGEN) does not pay dividend.
Guru Commentaries on NAS:AGEN
No articles.
Press Release
Articles on Agenus Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers